title: Eotaxin and RANTES expression by the dermal endothelium is associated with eosinophil infiltration after ivermectin treatment of onchocerciasis.
abstract: The roles of eotaxin, RANTES, and MCP-3 expression in eosinophil recruitment to the site of parasite killing that occurs following ivermectin treatment of onchocerciasis were assessed in the skin of 13 Onchocerca volvulus-infected subjects and two noninfected controls before and after ivermectin treatment. Adverse reactions in infected subjects were associated with the appearance of eosinophils in the dermis as part of a perivascular inflammatory infiltrate. Although no expression of RANTES and eotaxin was seen in dermal vascular endothelial cells in biopsies taken before treatment (nor at any time in the skin of uninfected controls), endothelial expression of both eotaxin and RANTES was noted by 24 h following treatment. While RANTES expression was transient, eotaxin expression increased in parallel with increasing eosinophil recruitment up to 60 h posttreatment. These observations indicate that endothelial expression of eotaxin and RANTES may have an important role in eosinophil recruitment into the skin during helminth-killing reactions.
authors.affiliation: Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892-0425, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Cooper
authors.forename: L A
authors.initials: LA
authors.lastname: Beck
authors.forename: I
authors.initials: I
authors.lastname: Espinel
authors.forename: N M
authors.initials: NM
authors.lastname: Deyampert
authors.forename: A
authors.initials: A
authors.lastname: Hartnell
authors.forename: P J
authors.initials: PJ
authors.lastname: Jose
authors.forename: W
authors.initials: W
authors.lastname: Paredes
authors.forename: R H
authors.initials: RH
authors.lastname: Guderian
authors.forename: T B
authors.initials: TB
authors.lastname: Nutman
mesh_terms: D000328:Adult; D000818:Animals; D001706:Biopsy; D054413:Chemokine CCL11; D018946:Chemokine CCL5 / Q000096:biosynthesis; D018925:Chemokines / Q000096:biosynthesis*; D019742:Chemokines, CC; D002634:Chemotaxis, Leukocyte; D016207:Cytokines / Q000096:biosynthesis; D062109:Dermatologic Surgical Procedures; D020405:Dermis / Q000098:blood supply / Q000276:immunology*; D004484:Ecuador; D004730:Endothelium, Vascular / Q000276:immunology*; D004802:Eosinophilia / Q000276:immunology*; D005260:Female; D006801:Humans; D007559:Ivermectin / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D017181:Onchocerca volvulus / Q000276:immunology*; D009855:Onchocerciasis / Q000188:drug therapy / Q000276:immunology*
chemical_list: C515456:CCL11 protein, human; D054413:Chemokine CCL11; D018946:Chemokine CCL5; D018925:Chemokines; D019742:Chemokines, CC; D016207:Cytokines; D007559:Ivermectin